Insulet Co. (NASDAQ:PODD) Shares Purchased by Mizuho Securities USA LLC

Mizuho Securities USA LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 46.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,648 shares of the medical instruments supplier’s stock after buying an additional 2,101 shares during the quarter. Mizuho Securities USA LLC’s holdings in Insulet were worth $1,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PODD. iA Global Asset Management Inc. increased its holdings in shares of Insulet by 131.1% during the fourth quarter. iA Global Asset Management Inc. now owns 4,756 shares of the medical instruments supplier’s stock valued at $1,242,000 after acquiring an additional 2,698 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Insulet by 1.0% in the fourth quarter. Teacher Retirement System of Texas now owns 18,328 shares of the medical instruments supplier’s stock worth $4,785,000 after buying an additional 187 shares during the last quarter. Royal London Asset Management Ltd. lifted its stake in shares of Insulet by 9.0% during the fourth quarter. Royal London Asset Management Ltd. now owns 31,283 shares of the medical instruments supplier’s stock worth $8,167,000 after buying an additional 2,572 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in shares of Insulet during the fourth quarter valued at $603,000. Finally, Chesapeake Capital Corp IL acquired a new position in shares of Insulet in the 4th quarter valued at $422,000.

Analyst Upgrades and Downgrades

A number of analysts have commented on PODD shares. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Citigroup lifted their target price on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Raymond James reiterated an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target for the company. Finally, Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $292.06.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by company insiders.

Insulet Stock Down 0.5 %

Shares of NASDAQ PODD opened at $272.71 on Wednesday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s 50-day simple moving average is $272.27 and its 200-day simple moving average is $258.19. The firm has a market cap of $19.15 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.